Telix Pharmaceuticals Limited - American Depositary Shares (TLX) closed at $9.03 on October 27, 2026, up 0.4% from the previous close, on volume of 219,679 shares (30-day average 448,097).
Data as of October 27, 2026.
Telix Pharmaceuticals (TLPPF) Gets a Buy from Citi
TipRanks (Mon, 26-Oct 8:26 PM ET)
Ord Minnett Remains a Buy on Telix Pharmaceuticals (TLPPF)
TipRanks (Mon, 26-Oct 8:15 PM ET)
Telix Pharmaceuticals (TLPPF) Receives a Buy from Jarden
TipRanks (Thu, 22-Oct 9:47 PM ET)
Telix Reports Third Quarter 2026 Financial Performance
Globe Newswire (Tue, 20-Oct 6:10 PM ET)
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Globe Newswire (Mon, 19-Oct 1:30 AM ET)
Globe Newswire (Fri, 9-Oct 7:45 AM ET)
Globe Newswire (Tue, 6-Oct 6:30 AM ET)
Market Chameleon (Mon, 21-Sep 3:32 AM ET)
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Globe Newswire (Sun, 20-Sep 8:55 PM ET)
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
Globe Newswire (Mon, 14-Sep 6:30 AM ET)
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Telix Pharmaceuticals Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol TLX.
As of October 27, 2026, TLX stock price climbed to $9.03 with 219,679 million shares trading.
TLX has a beta of 1.36, meaning it tends to be more sensitive to market movements. TLX has a correlation of 0.10 to the broad based SPY ETF.
TLX has a market cap of $3.07 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that TLX belongs to (by Net Assets): APIE.
TLX has underperformed the market in the last year with a price return of -16.5% while the SPY ETF gained +14.8%. TLX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.6% and -20.0%, respectively, while the SPY returned +4.4% and -1.1%, respectively.
TLX support price is $8.81 and resistance is $9.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLX shares will trade within this expected range on the day.
